PCSK9 and atherosclerosis: Addition of ezetimibe or proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is recommended if the LDL-C remains above goal (based on the degree of risk, ESC guidelines give a goal of either <55 or <40 mg/dL in those with recurrent ASCVD events) [7].